Samsung Biologics to Contract Develop Pamphsin's Anticancer and Neovascularization Therapeutics

[Asia Economy Reporter Cho Hyun-ui] Samsung Biologics announced on the 6th that it has taken on the contract development (CDO) of PharmAbcine's anti-cancer and pathological neovascularization treatment candidate substance PMC-402.

Samsung Biologics will provide full CDO services from cell line development of PMC-402, process development, clinical sample production, support for Investigational New Drug (IND) application submission, to non-clinical and global clinical material production.

PMC-402 is a substance that helps normalize pathological neovascularization, which are newly proliferated blood vessels such as capillaries. Pathological neovascularization is known to be highly leaky and mainly appears in various tumors and age-related macular degeneration.

Yoo Jin-san, CEO of PharmAbcine, stated, "Through preliminary research, we confirmed the anti-cancer effects of PMC-402 both as a monotherapy and in combination with immune checkpoint inhibitors." He added, "It is also expected to be effective for ophthalmic diseases caused by abnormal blood vessels such as diabetic retinopathy and age-related macular degeneration." He further said, "Starting this year, we will conduct safety verification tests and aim to enter global Phase 1 clinical trials next year to challenge new drug development."

Kim Tae-han, CEO of Samsung Biologics, said, "We hope that domestic and international bio ventures will accelerate product development through strategic partnerships with Samsung Biologics and focus more on their core business of candidate substance discovery to achieve greater results."